1-3 of 3 results for subject:Methylphenidate
Librarians' tools
- Search time
- 0.162 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Methylphenidate
- We searched for
- subject_t:Methylphenidate OR subject_t:"Concerta XL" OR subject_t:"Methylphenidate hydrochloride" OR subject_t:Ritalin OR subject_ses:12526
Primary member
X
Robinson, Iris
Type
House
Session
Year
Department
Member
Primary member
More
Robinson, Iris (3)
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Northern Ireland how many young children and young adults in the Province are on Ritalin; and what alternative treatments are being offered.
To ask the Secretary of State for Northern Ireland how many young children and young adults in the Province are on Ritalin; and what alternative treatments are being offered.
Asked by
Iris Robinson
(Democratic Unionist Party)
Answered by
Paul Goggins
(Labour)
Answering body
Northern Ireland Office
Type
Written questions
Status
Answered
Tabled on
28 June 2006
For answer on
3 July 2006
Answered on
5 July 2006
The Department of Health, Social Services and Public Safety does not hold age specific data on the prescribing of Ritalin. A young person should have a full assessment and ideally, prior to prescription of medication, should have tried some behavioural management techniques, parental support and advice and possibly dietary advice. This would be provided through community paediatrics or child psychiatry.
Subjects
Northern Ireland; Methylphenidate
Date
5 July 2006
Reference
82102; 448 c1184W
House
House of Commons
To ask the Secretary of State for Health, if he plans to investigate the extent of methylphenidate prescribing in the UK. - Includes table and figures.
To ask the Secretary of State for Health, if he plans to investigate the extent of methylphenidate prescribing in the UK. - Includes table and figures.
Asked by
Iris Robinson
(Democratic Unionist Party)
Answered by
Stephen Ladyman
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
12 September 2003
For answer on
6 October 2003
Answered on
6 October 2003
Mrs. Iris Robinson: To ask the Secretary of State for Health if he plans to investigate the extent of Methylphenidate prescribing in
the UK. [130259]
Dr. Ladyman: Information is collected on the number of prescription items of all Methylphenidate drugs dispensed in the community.
The data includes prescriptions prescribed in general practitioner practices, and prescriptions prescribed in hospitals that have
been dispensed in the community. Private prescriptions, and prescriptions dispensed in hospitals are not included. Numbers of
prescriptions in England for the years 1997 to 2002 are set out in the table.
_________________________________________________________________________________________________.
Items (Thousand)
1997 92.1
1998 126.6
1999 158.0
2000 186.2
2001 208.5
2002 254.0
_________________________________________________________________________________________________.
In 2000, the National Institute for Clinical Excellence (NICE) made an appraisal of the use of Methylphenidate in the treatment of
attention deficit hyperactivity disorder (ADHD). NICE estimated that approximately 1 per cent. of all school-aged children-- about
69,000 of 6 to 16-year-olds in England met the diagnostic criteria for Hyperkinetic Disorder, the more severe type ADHD, of whom
some 45,000 might benefit from Methylphenidate were not receiving this treatment. A review of the appraisal is planned for this
year.
Subjects
Drugs; Prescription drugs; Methylphenidate
Date
6 October 2003
Reference
130259; 410 c1320W
House
House of Commons
To ask the Secretary of State for Health, what the (a) short and (b) long-term adverse effects are described with methylphenidate.
To ask the Secretary of State for Health, what the (a) short and (b) long-term adverse effects are described with methylphenidate.
Asked by
Iris Robinson
(Democratic Unionist Party)
Answered by
Stephen Ladyman
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
12 September 2003
For answer on
6 October 2003
Answered on
6 October 2003
Mrs. Iris Robinson: To ask the Secretary of State for Health what the (a) short and (b) long-term adverse effects are described with
Methylphenidate. [130260]
Dr. Ladyman: Methylphenidate (sold in the UK as Ritalin, Equasym and Concerta XL) is licensed for use in children over six years of
age as part of a comprehensive treatment programme for attention deficit hyperactivity disorder, where remedial measures alone prove
insufficient.
The most common short-term adverse effects generally occur at the beginning of treatment, and include central nervous system
effects, such as nervousness and insomnia, and gastro-intestinal effects, such as abdominal pain, nausea and vomiting.
The long-term safety and efficacy profiles of methylphenidate are not fully known. This is reflected in the product information of
Ritalin provided to prescribers which advises that patients requiring long- term therapy should be carefully monitored. It warns of
the risk of moderately reduced weight gain and slight growth retardation with the long-term use of stimulants in children and that
careful monitoring of growth is recommended. It also recommends that blood tests should be performed periodically during long-term
use.
Subjects
Drugs; Side effects; Methylphenidate
Date
6 October 2003
Reference
130260; 410 c1320-1W
House
House of Commons